as of 11-20-2026 3:45pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 28.7B | IPO Year: | 2021 |
| Target Price: | $50.82 | AVG Volume (30 days): | 7.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | -125.00 |
| 52 Week Low/High: | $19.96 - $42.50 | Next Earning Date: | 11-09-2026 |
| Revenue: | $8,260,000 | Revenue Growth: | -71.57% |
| Revenue Growth (this year): | 1870.25% | Revenue Growth (next year): | 271.46% |
| P/E Ratio: | -73.49 | Index: | N/A |
| Free Cash Flow: | -758558000.0 | FCF Growth: | N/A |
CFO
Avg Cost/Share
$41.80
Shares
175,000
Total Value
$7,323,271.90
Owned After
351,851
CFO
Avg Cost/Share
$41.20
Shares
125,000
Total Value
$5,150,000.00
Owned After
351,851
SEC Form 4
President & Immunovant CEO
Avg Cost/Share
$40.72
Shares
187,943
Total Value
$7,617,074.36
Owned After
811,211
President & Immunovant CEO
Avg Cost/Share
$36.31
Shares
200,000
Total Value
$7,262,000.00
Owned After
811,211
SEC Form 4
President & Immunovant CEO
Avg Cost/Share
$36.59
Shares
200,000
Total Value
$7,318,000.00
Owned After
811,211
SEC Form 4
President & Immunovant CEO
Avg Cost/Share
$35.26
Shares
200,000
Total Value
$7,022,667.52
Owned After
811,211
Director
Avg Cost/Share
$36.33
Shares
17,750
Total Value
$640,861.00
Owned After
14,954
Director
Avg Cost/Share
$40.07
Shares
5,112
Total Value
$203,152.16
Owned After
36,508
Director
Avg Cost/Share
$40.02
Shares
4,938
Total Value
$196,229.70
Owned After
14,954
Director
Avg Cost/Share
$39.90
Shares
20,000
Total Value
$798,000.00
Owned After
36,508
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Pulik Richard | ROIV | CFO | Nov 11, 2026 | Sell | $41.80 | 175,000 | $7,323,271.90 | 351,851 | |
| Pulik Richard | ROIV | CFO | Nov 10, 2026 | Sell | $41.20 | 125,000 | $5,150,000.00 | 351,851 | |
| Venker Eric | ROIV | President & Immunovant CEO | Nov 10, 2026 | Sell | $40.72 | 187,943 | $7,617,074.36 | 811,211 | |
| Venker Eric | ROIV | President & Immunovant CEO | Nov 3, 2026 | Sell | $36.31 | 200,000 | $7,262,000.00 | 811,211 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 28, 2026 | Sell | $36.59 | 200,000 | $7,318,000.00 | 811,211 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 20, 2026 | Sell | $35.26 | 200,000 | $7,022,667.52 | 811,211 | |
| Epperly Melissa B, | ROIV | Director | Oct 1, 2026 | Sell | $36.33 | 17,750 | $640,861.00 | 14,954 | |
| Fitzgerald Meghan | ROIV | Director | Sep 15, 2026 | Sell | $40.07 | 5,112 | $203,152.16 | 36,508 | |
| Epperly Melissa B, | ROIV | Director | Sep 15, 2026 | Sell | $40.02 | 4,938 | $196,229.70 | 14,954 | |
| Fitzgerald Meghan | ROIV | Director | Sep 8, 2026 | Sell | $39.90 | 20,000 | $798,000.00 | 36,508 |
SEC 8-K filings with transcript text
Nov 9, 2026 · 100% conf.
1D
-0.27%
$40.28
Act: +2.28%
5D
-5.16%
$38.31
20D
+1.17%
$40.87
roiv-20261109
false000163508800016350882026-11-092026-11-09
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 9, 2026
Roivant Sciences Ltd.
(Exact Name of Registrant as Specified in Charter)
Bermuda001-4078298-1173944
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
7th Floor
50 Broadway
London SW1H 0DB
United Kingdom
(Addresses of Principal Executive Offices, and Zip Code)
+44 207 400 3347
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Shares, $0.0000000341740141 per shareROIV The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On November 9, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth under this “Item 2.02 Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description of Exhibit
99.1 Roivant Science Ltd. Press Release, dated November 9, 2026
104Cover Page Interactive Data File (embedded with Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory
Dated: November 9, 2026
Aug 6, 2026 · 100% conf.
1D
+2.65%
$36.05
Act: +3.47%
5D
+3.97%
$36.52
20D
+9.51%
$38.46
roiv-20260806
false000163508800016350882026-08-062026-08-06
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 6, 2026
Roivant Sciences Ltd.
(Exact Name of Registrant as Specified in Charter)
Bermuda001-4078298-1173944
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
7th Floor
50 Broadway
London SW1H 0DB
United Kingdom
(Addresses of Principal Executive Offices, and Zip Code)
+44 207 400 3347
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Shares, $0.0000000341740141 per shareROIV The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth under this “Item 2.02 Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description of Exhibit
99.1 Roivant Science Ltd. Press Release, dated August 6, 2026
104Cover Page Interactive Data File (embedded with Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory
Dated: August 6, 2026
May 20, 2026 · 100% conf.
1D
+0.22%
$32.48
Act: -4.72%
5D
-4.85%
$30.84
Act: -7.87%
20D
+1.90%
$33.03
Act: -3.02%
roiv-20260520
false000163508800016350882026-05-202026-05-200001635088roiv:WhollyOwnedSubsidiariesAddressNYMember2026-05-202026-05-200001635088roiv:WhollyOwnedSubsidiariesAddressSwitzerlandMember2026-05-202026-05-20
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 20, 2026
Roivant Sciences Ltd.
(Exact Name of Registrant as Specified in Charter)
Bermuda001-4078298-1173944
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
7th Floor
50 Broadway
London SW1H 0DB
United Kingdom
1 Pennsylvania Plaza
Floor 54
New York, NY 10119 United States1
Viaduktstrasse 8
4051 Basel
Switzerland1
(Addresses of Principal Executive Offices, and Zip Code)
+44 207 400 3347
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Shares, $0.0000000341740141 per shareROIV The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
1 Addresses of wholly-owned subsidiaries of the Registrant.
Item 2.02 Results of Operations and Financial Condition.
On May 20, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth under this “Item 2.02 Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description of Exhibit
99.1 Roivant Science Ltd. Press Release, dated May 20, 2026
104Cover Page Interactive Data File (embedded with Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory
Dated: May 20, 2026
See how ROIV stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.